Donah Zachariah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Donah Zachariah has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Chiara Latini
Cardio Center, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy (A. Mangieri, A. Latini)
2 shared publications Antonio Frontera
IRCCS Humanitas Research Hospital Electrophysiology and Electrostimulation Unit
2 shared publications- Antonio Taormina
IRCCS Humanitas Research Hospital Electrophysiology and Electrostimulation Unit
2 shared publications Gabriele Pinna
Istituto Clinico Humanitas, Rozzano, Italy
2 shared publicationsAdrian Morley-Davies
Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, UK
1 shared publicationAlessandra Marzi
Department of Arrhythmology, IRCCS San Raffaele Hospital, Milan, Italy
1 shared publication
Latest Publications
- 13 September 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (6) , 1401-1410
The functional substrate in patients with atrial fibrillation is predictive of recurrences after catheter ablation
- 13 September 2024
- Published by Elsevier in Heart Rhythm
- Vol. 22 (6) , 1401-1410
The functional substrate in patients with atrial fibrillation is predictive of recurrences after catheter ablation
- Open Access
- 23 August 2023
- Published by Wiley
Incidence and predictors of post-surgery atrial fibrillation occurrence: a cohort study in 53,387 patients
INTRODUCTION. Post-operative atrial fibrillation (POAF) represents the most common arrhythmia reported in the days following surgery. We aimed to investigate the incidence of POAF in the 28 days after surgery and determine its predictors, with a specific focus on inflammation markers. METHODS. We performed a retrospective single center cohort study that included consecutive adult patients who underwent a major surgical procedure between January 2016 to January 2020. Patients were divided into four subgroups according to the type of surgery: (I) orthopedic, (II) non-thoracic non-abdominal, (III) abdominal and esophageal, or (IV) lung and cardiovascular surgery. RESULTS. Among 53,387 included patients (48.8% male, mean age 59 ± 15.9 years), POAF occurred in 570 (1.1%) with a mean latency after surgery of 3.4±2.6 days. Ninety patients died (0.17%) after a mean of 13.7±8.4 days. The 28-day arrhythmia-free survival was lower in patients undergoing lung and cardiovascular surgery ( pCONCLUSIONS. Lung and cardiovascular surgery had the highest risk of POAF in the presented cohort. CRP was an independent predictor of POAF and post-surgery inflammation status may represent a major driver in the pathophysiology.
- 23 August 2023
- Published by Wiley
Open AccessIncidence and predictors of post-surgery atrial fibrillation occurrence: a cohort study in 53,387 patients
INTRODUCTION. Post-operative atrial fibrillation (POAF) represents the most common arrhythmia reported in the days following surgery. We aimed to investigate the incidence of POAF in the 28 days after surgery and determine its predictors, with a specific focus on inflammation markers. METHODS. We performed a retrospective single center cohort study that included consecutive adult patients who underwent a major surgical procedure between January 2016 to January 2020. Patients were divided into four subgroups according to the type of surgery: (I) orthopedic, (II) non-thoracic non-abdominal, (III) abdominal and esophageal, or (IV) lung and cardiovascular surgery. RESULTS. Among 53,387 included patients (48.8% male, mean age 59 ± 15.9 years), POAF occurred in 570 (1.1%) with a mean latency after surgery of 3.4±2.6 days. Ninety patients died (0.17%) after a mean of 13.7±8.4 days. The 28-day arrhythmia-free survival was lower in patients undergoing lung and cardiovascular surgery ( pCONCLUSIONS. Lung and cardiovascular surgery had the highest risk of POAF in the presented cohort. CRP was an independent predictor of POAF and post-surgery inflammation status may represent a major driver in the pathophysiology.
- 11 August 2022
- Published by Elsevier in Heart Rhythm
- Vol. 19 (12) , 2075-2083
Significance of abnormal and late ventricular signals in ventricular tachycardia ablation of ischemic and nonischemic cardiomyopathies
- 11 August 2022
- Published by Elsevier in Heart Rhythm
- Vol. 19 (12) , 2075-2083
Significance of abnormal and late ventricular signals in ventricular tachycardia ablation of ischemic and nonischemic cardiomyopathies
- 9 February 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (4) , 369-370
Safety of AF ablation–its evolution over time and lessons from down under
- 9 February 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (4) , 369-370
Safety of AF ablation–its evolution over time and lessons from down under
- Open Access
- 5 October 2021
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 22 (1) , 18-23
A comparison of clinical outcomes following atrial fibrillation ablation for heart failure patients with preserved or reduced left ventricular function: A systematic review and meta-analysis
- 5 October 2021
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 22 (1) , 18-23
Open AccessA comparison of clinical outcomes following atrial fibrillation ablation for heart failure patients with preserved or reduced left ventricular function: A systematic review and meta-analysis
- 1 January 2021
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 37 (1) , 86-93
Sex Disparities in the Choice of Cardiac Resynchronization Therapy Device: An Analysis of Trends, Predictors, and Outcomes
- 1 January 2021
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 37 (1) , 86-93
Sex Disparities in the Choice of Cardiac Resynchronization Therapy Device: An Analysis of Trends, Predictors, and Outcomes
- Open Access
- 14 December 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (12) , e0188713
Monitoring of arrhythmia and sudden death in a hemodialysis population: The CRASH-ILR Study
It has been suggested that sudden cardiac death (SCD) contributes around 50% of cardiovascular and 27% of all-cause mortality in hemodialysis patients. The true burden of arrhythmias and arrhythmic deaths in this population, however, remains poorly characterised. Cardio Renal Arrhythmia Study in Hemodialysis (CRASH-ILR) is a prospective, implantable loop recorder single centre study of 30 established hemodialysis patients and one of the first to provide long-term ambulatory ECG monitoring. 30 patients (60% male) aged 68±12 years receiving hemodialysis for 45±40 months with varied etiology (diabetes 37%, hypertension 23%) and left ventricular ejection fraction (LVEF) 55±8% received a Reveal XT implantable loop recorder (Medtronic, USA) between August 2011 and October 2014. ECG data from loop recorders were transmitted at each hemodialysis session using a remote monitoring system. Primary outcome was SCD or implantation of a (tachy or bradyarrhythmia controlling) device and secondary outcome, the development of arrhythmia necessitating medical intervention. During 379,512 hours of continuous ECG monitoring (mean 12,648±9,024 hours/patient), there were 8 deaths—2 SCD and 6 due to generalised deterioration/sepsis. 5 (20%) patients had a primary outcome event (2 SCD, 3 pacemaker implantations for bradyarrhythmia). 10 (33%) patients reached an arrhythmic primary or secondary end point. Median event free survival for any arrhythmia was 2.6 years (95% confidence intervals 1.6–3.6 years). The findings confirm the high mortality rate seen in hemodialysis populations and contrary to initial expectations, bradyarrhythmias emerged as a common and potentially significant arrhythmic event.
- 14 December 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (12) , e0188713
Open AccessMonitoring of arrhythmia and sudden death in a hemodialysis population: The CRASH-ILR Study
It has been suggested that sudden cardiac death (SCD) contributes around 50% of cardiovascular and 27% of all-cause mortality in hemodialysis patients. The true burden of arrhythmias and arrhythmic deaths in this population, however, remains poorly characterised. Cardio Renal Arrhythmia Study in Hemodialysis (CRASH-ILR) is a prospective, implantable loop recorder single centre study of 30 established hemodialysis patients and one of the first to provide long-term ambulatory ECG monitoring. 30 patients (60% male) aged 68±12 years receiving hemodialysis for 45±40 months with varied etiology (diabetes 37%, hypertension 23%) and left ventricular ejection fraction (LVEF) 55±8% received a Reveal XT implantable loop recorder (Medtronic, USA) between August 2011 and October 2014. ECG data from loop recorders were transmitted at each hemodialysis session using a remote monitoring system. Primary outcome was SCD or implantation of a (tachy or bradyarrhythmia controlling) device and secondary outcome, the development of arrhythmia necessitating medical intervention. During 379,512 hours of continuous ECG monitoring (mean 12,648±9,024 hours/patient), there were 8 deaths—2 SCD and 6 due to generalised deterioration/sepsis. 5 (20%) patients had a primary outcome event (2 SCD, 3 pacemaker implantations for bradyarrhythmia). 10 (33%) patients reached an arrhythmic primary or secondary end point. Median event free survival for any arrhythmia was 2.6 years (95% confidence intervals 1.6–3.6 years). The findings confirm the high mortality rate seen in hemodialysis populations and contrary to initial expectations, bradyarrhythmias emerged as a common and potentially significant arrhythmic event.
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 249, 313-318
Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 249, 313-318
Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study
- 31 July 2013
- Published by Wiley in Journal of Renal Care
- Vol. 39 (3) , 128-139
CLINICAL UTILITY OF BIOMARKERS IN CHRONIC KIDNEY DISEASE AND CHRONIC HEART FAILURE
Biomarkers have an increasingly important clinical role in managing patients with heart failure as well as those with kidney disease, both common conditions with generally poor prognostic outcomes and huge impacts on healthcare economics. For patients with chronic heart failure, biomarkers have become centre place in streamlining diagnostic pathways as well as identifying those with worse prognosis. There is much interest in the role for biomarkers in identifying patients at risk of acute kidney injury, although a number of these currently remain as research tools or are in the early stages of evaluation in clinical practice. Patients with cardiorenal syndrome represent a particular challenge to the clinician, and recent studies have suggested a valuable clinical role for certain biomarkers in this setting, either on their own or in combination. This paper will focus on biomarkers with a current clinical role in patients with cardiorenal disease (natriuretic peptides and neutrophil gelatinase-associated lipocalin), although brief reference will be made to other biomarkers with potential future application.
- 31 July 2013
- Published by Wiley in Journal of Renal Care
- Vol. 39 (3) , 128-139
CLINICAL UTILITY OF BIOMARKERS IN CHRONIC KIDNEY DISEASE AND CHRONIC HEART FAILURE
Biomarkers have an increasingly important clinical role in managing patients with heart failure as well as those with kidney disease, both common conditions with generally poor prognostic outcomes and huge impacts on healthcare economics. For patients with chronic heart failure, biomarkers have become centre place in streamlining diagnostic pathways as well as identifying those with worse prognosis. There is much interest in the role for biomarkers in identifying patients at risk of acute kidney injury, although a number of these currently remain as research tools or are in the early stages of evaluation in clinical practice. Patients with cardiorenal syndrome represent a particular challenge to the clinician, and recent studies have suggested a valuable clinical role for certain biomarkers in this setting, either on their own or in combination. This paper will focus on biomarkers with a current clinical role in patients with cardiorenal disease (natriuretic peptides and neutrophil gelatinase-associated lipocalin), although brief reference will be made to other biomarkers with potential future application.